Molecular Pharmacology Stock Net Income
| MLPH Stock | USD 0.0004 0.00 0.00% |
As of the 3rd of March, Molecular Pharmacology secures the Risk Adjusted Performance of 0.1218, standard deviation of 236.86, and Mean Deviation of 70.83. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Molecular Pharmacology, as well as the relationship between them.
Molecular Pharmacology's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Molecular Pharmacology's valuation are provided below:Molecular Pharmacology does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Molecular |
Molecular Pharmacology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Molecular Pharmacology's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Molecular Pharmacology.
| 12/03/2025 |
| 03/03/2026 |
If you would invest 0.00 in Molecular Pharmacology on December 3, 2025 and sell it all today you would earn a total of 0.00 from holding Molecular Pharmacology or generate 0.0% return on investment in Molecular Pharmacology over 90 days. Molecular Pharmacology Limited, a development stage company, develops and commercializes pain and inflammation managemen... More
Molecular Pharmacology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Molecular Pharmacology's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Molecular Pharmacology upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1459 | |||
| Maximum Drawdown | 1936.91 | |||
| Potential Upside | 25.0 |
Molecular Pharmacology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Molecular Pharmacology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Molecular Pharmacology's standard deviation. In reality, there are many statistical measures that can use Molecular Pharmacology historical prices to predict the future Molecular Pharmacology's volatility.| Risk Adjusted Performance | 0.1218 | |||
| Jensen Alpha | 33.58 | |||
| Total Risk Alpha | 12.65 | |||
| Treynor Ratio | 2.33 |
Molecular Pharmacology March 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1218 | |||
| Market Risk Adjusted Performance | 2.34 | |||
| Mean Deviation | 70.83 | |||
| Coefficient Of Variation | 683.71 | |||
| Standard Deviation | 236.86 | |||
| Variance | 56100.5 | |||
| Information Ratio | 0.1459 | |||
| Jensen Alpha | 33.58 | |||
| Total Risk Alpha | 12.65 | |||
| Treynor Ratio | 2.33 | |||
| Maximum Drawdown | 1936.91 | |||
| Potential Upside | 25.0 | |||
| Skewness | 7.2 | |||
| Kurtosis | 54.24 |
Molecular Pharmacology Backtested Returns
Molecular Pharmacology is out of control given 3 months investment horizon. Molecular Pharmacology has Sharpe Ratio of 0.16, which conveys that the firm had a 0.16 % return per unit of risk over the last 3 months. We were able to interpolate data for eighteen different technical indicators, which can help you to evaluate if expected returns of 23.33% are justified by taking the suggested risk. Use Molecular Pharmacology Standard Deviation of 236.86, mean deviation of 70.83, and Risk Adjusted Performance of 0.1218 to evaluate company specific risk that cannot be diversified away. Molecular Pharmacology holds a performance score of 12 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 14.87, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Molecular Pharmacology will likely underperform. Use Molecular Pharmacology variance, skewness, as well as the relationship between the Skewness and relative strength index , to analyze future returns on Molecular Pharmacology.
Auto-correlation | -0.17 |
Insignificant reverse predictability
Molecular Pharmacology has insignificant reverse predictability. Overlapping area represents the amount of predictability between Molecular Pharmacology time series from 3rd of December 2025 to 17th of January 2026 and 17th of January 2026 to 3rd of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Molecular Pharmacology price movement. The serial correlation of -0.17 indicates that over 17.0% of current Molecular Pharmacology price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.17 | |
| Spearman Rank Test | -0.55 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Molecular Pharmacology reported net income of (116,928). This is 100.03% lower than that of the Biotechnology sector and 100.17% lower than that of the Health Care industry. The net income for all United States stocks is 100.02% higher than that of the company.
Molecular Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Molecular Pharmacology's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Molecular Pharmacology could also be used in its relative valuation, which is a method of valuing Molecular Pharmacology by comparing valuation metrics of similar companies.Molecular Pharmacology is currently under evaluation in net income category among its peers.
Molecular Fundamentals
| Return On Asset | -5.69 | |||
| Current Valuation | 221.59 K | |||
| Shares Outstanding | 111.55 M | |||
| Price To Earning | (0.80) X | |||
| EBITDA | (98.11 K) | |||
| Net Income | (116.93 K) | |||
| Cash And Equivalents | 1.52 K | |||
| Total Debt | 175.33 K | |||
| Current Ratio | 0.28 X | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (105.41 K) | |||
| Beta | 42.97 | |||
| Market Capitalization | 26.77 K | |||
| Total Asset | 8.97 K | |||
| Working Capital | (2.1 M) | |||
| Current Asset | 9 K | |||
| Current Liabilities | 2.11 M | |||
| Net Asset | 8.97 K |
About Molecular Pharmacology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Molecular Pharmacology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Molecular Pharmacology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Molecular Pharmacology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Molecular Pink Sheet
Molecular Pharmacology financial ratios help investors to determine whether Molecular Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Molecular with respect to the benefits of owning Molecular Pharmacology security.